These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 33205384)

  • 1. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2020 Oct; 17(4):1393-1405. PubMed ID: 33205384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing in Parkinson's Disease.
    Athauda D; Foltynie T
    CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status and future directions of clinical trials in Parkinson's disease.
    Söderbom G
    Int Rev Neurobiol; 2020; 154():153-188. PubMed ID: 32739003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Frontiers in Parkinson's Disease: From Genetics to the Clinic.
    Shihabuddin LS; Brundin P; Greenamyre JT; Stephenson D; Sardi SP
    J Neurosci; 2018 Oct; 38(44):9375-9382. PubMed ID: 30381429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
    Palmas MF; Ena A; Burgaletto C; Casu MA; Cantarella G; Carboni E; Etzi M; De Simone A; Fusco G; Cardia MC; Lai F; Picci L; Tweedie D; Scerba MT; Coroneo V; Bernardini R; Greig NH; Pisanu A; Carta AR
    Neurotherapeutics; 2022 Jan; 19(1):305-324. PubMed ID: 35072912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for Parkinson's disease: promising agents in early clinical development.
    Fabbri M; Perez-Lloret S; Rascol O
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1249-1267. PubMed ID: 32853086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old wines in new bottles: Repurposing opportunities for Parkinson's disease.
    Kakkar AK; Singh H; Medhi B
    Eur J Pharmacol; 2018 Jul; 830():115-127. PubMed ID: 29689247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in therapeutic strategies for Parkinson's disease.
    Kulisevsky J; Oliveira L; Fox SH
    Curr Opin Neurol; 2018 Aug; 31(4):439-447. PubMed ID: 29746402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.